[Almanac 2011: Valvular heart disease. Review of select studies that have driven recent advances in clinical cardiology: in the care of the Editors' Network Task Force of the European Society of Cardiology].
Department of Cardiology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. raphael.rosenhek@meduniwien.ac.at
Raphael
R
Rosenhek
D000367:Age Factors; D000503:Almanacs as Topic; D001022:Aortic Valve Insufficiency / Q000628:therapy; D001024:Aortic Valve Stenosis / Q000628:therapy; D001317:Austria / Q000453:epidemiology; D015415:Biomarkers / Q000097:blood; D035843:Biomedical Research; D006348:Cardiac Surgical Procedures / Q000379:methods; D002309:Cardiology / Q000639:trends; D004696:Endocarditis / Q000628:therapy; D005464:Fluorobenzenes / Q000627:therapeutic use*; D006349:Heart Valve Diseases / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000150:complications; D008944:Mitral Valve Insufficiency / Q000628:therapy; D045283:Natriuretic Agents / Q000097:blood; D020097:Natriuretic Peptide, Brain / Q000097:blood; D010506:Periodicals as Topic; D015995:Prevalence; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D000068718:Rosuvastatin Calcium; D012720:Severity of Illness Index; D012907:Smoking / Q000009:adverse effects; D013449:Sulfonamides / Q000627:therapeutic use*; D014262:Tricuspid Valve Insufficiency / Q000628:therapy
D015415:Biomarkers; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D045283:Natriuretic Agents; D011743:Pyrimidines; D013449:Sulfonamides; D020097:Natriuretic Peptide, Brain; D000068718:Rosuvastatin Calcium